SGX Gets Boehringer Ingelheim Deal

Structural Genomix of San Diego, Calif., and Boehringer Ingelheim Pharmaceuticals said last week they started a two-year collaboration. Under the agreement, SGX will solve the three dimensional structures of protein targets provided by Boehringer. Subsequently, SGX will generate co-crystals with potential drug lead compounds.

Boehringer hopes that SGX's high-throughput protein structure determination platform will help it optimize lead compounds and improve drug candidates.


Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.